摘要
蒽环类药物具有抗瘤谱广、作用强、疗效高等优点,是抗肿瘤治疗中最有效的化疗药物之一,但其会产生心脏毒性、肝肾毒性、骨髓抑制、手足综合征等一系列不良反应。心脏毒性是其最严重的不良反应,大大影响了肿瘤患者的生存率和生存质量,使其临床应用受到一定限制。如何早期监测和减轻其心脏毒性已成为临床亟待解决的问题。本文旨在探讨蒽环类抗肿瘤药物引发心脏毒性的作用机制、早期监测及预防进展,以供临床参考。
Anthracyclines are among the most effective chemotherapeutic drugs in anti-tumor therapy because of their broad anti-tumor spectrum,strong action and high efficacy.However,anthracyclines may also cause many adverse reactions,such as cardiotoxicity,hepatorenal toxicity,myelosuppression,and hand-foot syndrome.Among these,cardiotoxicity is the most serious adverse reaction,and greatly affects the survival rate and quality of life of cancer patients and restricts their clinical application.Therefore,how to monitor and mitigate their cardiotoxicity at an early stage has become an urgent clinical problem.This paper aims to discuss the mechanism of action,early monitoring and progress in the prevention of cardiotoxicity induced by anthracycline antitumor drugs.
作者
李薇
徐晓红
LI Wei;XU Xiao-hong(Department of Ultrasound Medicine,Affiliated Hospital of Guangdong Medical University,Zhanjiang Guangdong 524000)
出处
《中南药学》
CAS
2024年第2期437-444,共8页
Central South Pharmacy
